The emerging role of toll-like receptor 4 in myocardial inflammation

Cell Death and Disease

Volumn 7, Issue 5, 2016, Pages

  Yang, Y ^a,b,c   Lv, J ^c   Jiang, S ^c   Ma, Z ^d   Wang, D ^b   Hu, W ^c   Deng, C ^a   Fan, C ^d   Di, S ^d   Sun, Y ^a   Yi, W ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; CARDIOTONIC AGENT; DISACCHARIDE; ERITORAN; FOLLISTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; MYD88 PROTEIN, HUMAN; SUGAR PHOSPHATE;

AUTOIMMUNE DISEASE; HUMAN; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VIRUS MYOCARDITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CLINICAL TRIAL (TOPIC); GENE EXPRESSION REGULATION; GENETICS; HEART FAILURE; IMMUNOLOGY; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; REPERFUSION INJURY;

ANIMALS; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DISACCHARIDES; FOLLISTATIN; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; METFORMIN; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL INFARCTION; MYOCARDITIS; MYOCARDIUM; NF-KAPPA B; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SUGAR PHOSPHATES; TOLL-LIKE RECEPTOR 4;

EID: 84982220163     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.140     Document Type: Review

References (88)

1. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis-diagnosis, treatment options, and current controversies. Nat Rev Cardiol 2015; 12: 670–680.
2. Saxena A, Russo I, Frangogiannis NG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res 2015; 167: 152–166.
3. Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, de Kleijn DP. The innate immune response in reperfused myocardium. Cardiovasc Res 2012; 94: 276–283.
4. Liu L, Wang Y, Cao ZY, Wang MM, Liu XM, Gao T et al. Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med 2015; 19: 2728–2740.
5. Venardos N, Nadlonek NA, Zhan Q, Weyant MJ, Reece TB, Meng X et al. Aortic valve calcification is mediated by a differential response of aortic valve interstitial cells to inflammation. J Surg Res 2014; 190: 1–8.
6. Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem 2015; 6: 209–217.
7. McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ Res 2015; 116: 1022–1033.
8. Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998; 10: 349–350.
9. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1–5.
10. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805–820.
11. Fairweather D, Frisancho-Kiss S. Mast cells and inflammatory heart disease: potential drug targets. Cardiovasc Hematol Disord Drug Targets 2008; 8: 80–90.
12. de Laat MA, Gruntmeir KJ, Pollitt CC, McGowan CM, Sillence MN, Lacombe VA. Hyperinsulinemia down-regulates TLR4 expression in the mammalian heart. Front Endocrinol (Lausanne) 2014; 5: 120.
13. Gawri R, Rosenzweig DH, Krock E, Ouellet JA, Stone LS, Quinn TM et al. High mechanical strain of primary intervertebral disc cells promotes secretion of inflammatory factors associated with disc degeneration and pain. Arthritis Res Ther 2014; 16: R21.
14. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 2014; 14: 546–558.
15. Xu D, Yan S, Wang H, Gu B, Sun K, Yang X et al. IL-29 enhances LPS/TLR4-mediated inflammation in rheumatoid arthritis. Cell Physiol Biochem 2015; 37: 27–34.
16. Li H, Huang LF, Wen C, Yang ZC, Chen CY. Roles of cardiac mast cells and Toll-like receptor 4 in viral myocarditis among mice. Zhongguo Dang Dai Er Ke Za Zhi 2013; 15: 896–902.
17. Senhaji N, Diakite B, Serbati N, Zaid Y, Badre W, Nadifi S. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms: new data and a meta-analysis. BMC Gastroenterol 2014; 14: 206.
18. Fairweather D, Yusung S, Frisancho S, Barrett M, Gatewood S, Steele R et al. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta-and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 2003; 170: 4731–4737.
19. Soraya H, Clanachan AS, Rameshrad M, Maleki-Dizaji N, Ghazi-Khansari M, Garjani A. Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. Eur J Pharmacol 2014; 737: 77–84.
20. Ding HS, Yang J, Chen P, Yang J, Bo SQ, Ding JW et al. The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis. Gene 2013; 527: 389–393.
21. Zeng Q, Song R, Ao L, Weyant MJ, Lee J, Xu D et al. Notch1 promotes the pro-osteogenic response of human aortic valve interstitial cells via modulation of ERK1/2 and nuclear factor-kappaB activation. Arterioscler Thromb Vasc Biol 2013; 33: 1580–1590.
22. Bagheri B, Sohrabi B, Movassaghpour AA, Mashayekhi S, Garjani A, Shokri M et al. Hydrocortisone reduces Toll-like receptor 4 expression on peripheral CD14+ monocytes in patients undergoing percutaneous coronary intervention. Iran Biomed J 2014; 18: 76–81.
23. Satoh S, Yada R, Inoue H, Omura S, Ejima E, Mori T et al. Toll-like receptor-4 is upregulated in plaque debris of patients with acute coronary syndrome more than Toll-like receptor-2. Heart Vessels 2014; 31: 1–5.
24. Steward R, McNally FJ, Schedl P. Isolation of the dorsal locus of Drosophila. Nature 1984; 311: 262–265.
25. Mitchell JA, Ryffel B, Quesniaux VF, Cartwright N, Paul-Clark M. Role of pattern-recognition receptors in cardiovascular health and disease. Biochem Soc Trans 2007; 35: 1449–1452.
26. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011; 108: 1133–1145.
27. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005; 28: 886–892.
28. Kang JY, Lee JO. Structural biology of the Toll-like receptor family. Annu Rev Biochem 2011; 80: 917–941.
29. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10–14.
30. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13: 933–940.
31. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol 2012; 12: 168–179.
32. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012; 37: 771–783.
33. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394–397.
34. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S et al. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005; 6: 565–570.
35. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667–672.
36. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1–14.
37. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5: 446–458.
38. Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA 2006; 103: 19794–19799.
39. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5: 156–164.
40. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: e61–e64.
41. Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E et al. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 2004; 292: 2339–2340.
42. Koch W, Hoppmann P, Pfeufer A, Schomig A, Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J 2006; 27: 2524–2529.
43. Edfeldt K, Bennet AM, Eriksson P, Frostegard J, Wiman B, Hamsten A et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25: 1447–1453.
44. Paul-Clark MJ, George PM, Gatheral T, Parzych K, Wright WR, Crawford D et al. Pharmacology and therapeutic potential of pattern recognition receptors. Pharmacol Ther 2012; 135: 200–215.
45. Ha T, Liu L, Kelley J, Kao R, Williams D, Li C. Toll-like receptors: new players in myocardial ischemia/reperfusion injury. Antioxid Redox Signal 2011; 15: 1875–1893.
46. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ et al. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol 2009; 85: 966–977.
47. Williams DL, Ozment-Skelton T, Li C. Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock 2006; 25: 432–439.
48. Flannery S, Bowie AG. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharmacol 2010; 80: 1981–1991.
49. Yamamoto T, Tsutsumi N, Tochio H, Ohnishi H, Kubota K, Kato Z et al. Functional assessment of the mutational effects of human IRAK4 and MyD88 genes. Mol Immunol 2014; 58: 66–76.
50. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010; 465: 885–890.
51. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3–9.
52. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353–364.
53. Vallejo JG. Role of toll-like receptors in cardiovascular diseases. Clin Sci (Lond) 2011; 121: 1–10.
54. Terrell AM, Crisostomo PR, Wairiuko GM, Wang M, Morrell ED, Meldrum DR. Jak/STAT/ SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. Shock 2006; 26: 226–234.
55. Tatematsu M, Ishii A, Oshiumi H, Horiuchi M, Inagaki F, Seya T et al. A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation. J Biol Chem 2010; 285: 20128–20136.
56. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006; 18: 3–9.
57. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 2003; 171: 4304–4310.
58. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004; 5: 503–507.
59. Riad A, Westermann D, Zietsch C, Savvatis K, Becher PM, Bereswill S et al. TRIF is a critical survival factor in viral cardiomyopathy. J Immunol 2011; 186: 2561–2570.
60. Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, Chen M et al. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 2005; 112: 2276–2285.
61. Bachmaier K, Toya S, Malik AB. Therapeutic administration of the chemokine CXCL1/KC abrogates autoimmune inflammatory heart disease. PLoS One 2014; 9: e89647.
62. Machino-Ohtsuka T, Tajiri K, Kimura T, Sakai S, Sato A, Yoshida T et al. Tenascin-C aggravates autoimmune myocarditis via dendritic cell activation and Th17 cell differentiation. J Am Heart Assoc 2014; 3: e001052.
63. Jenke A, Wilk S, Poller W, Eriksson U, Valaperti A, Rauch BH et al. Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc Res 2013; 99: 422–431.
64. Frangogiannis NG. Inflammation in cardiac injury, repair and regeneration. Curr Opin Cardiol 2015; 30: 240–245.
65. Haas B, Leonard F, Ernens I, Rodius S, Vausort M, Rolland-Turner M et al. Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products. J Cardiovasc Transl Res 2011; 4: 790–800.
66. Rohde D, Schon C, Boerries M, Didrihsone I, Ritterhoff J, Kubatzky KF et al. S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4. EMBO Mol Med 2014; 6: 778–794.
67. Schiopu A, Cotoi OS. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm 2013; 2013: 828354.
68. Zhang W, Lavine KJ, Epelman S, Evans SA, Weinheimer CJ, Barger PM et al. Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc 2015; 4: e001993.
69. van der Pouw Kraan TC, Bernink FJ, Yildirim C, Koolwijk P, Baggen JM, Timmers L et al. Systemic toll-like receptor and interleukin-18 pathway activation in patients with acute ST elevation myocardial infarction. J Mol Cell Cardiol 2014; 67: 94–102.
70. Lu M, Tang F, Zhang J, Luan A, Mei M, Xu C et al. Astragaloside IV attenuates injury caused by myocardial ischemia/reperfusion in rats via regulation of Toll-like receptor 4/nuclear factor-kappaB signaling pathway. Phytother Res 2015; 29: 599–606.
71. Cai W, Zhang Y, Li J, Wang J. Kappa-opioid receptor agonist U50, 488H attenuates myocardial ischemia-reperfusionvia modulating Toll-like receptor 4/nuclear factor-kappaB signaling in rat. Zhonghua Xin Xue Guan Bing Za Zhi 2014; 42: 866–872.
72. Liu QP, Pan KY, Zhou X, Yu HL, Han GL, Li YM et al. Dynamic expression of toll like receptor 2 and 4 in a rat model of myocardial ischemia/reperfusion injury. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2013; 29: 326–330.
73. Wang C, Sun H, Song Y, Ma Z, Zhang G, Gu X et al. Pterostilbene attenuates inflammation in rat heart subjected to ischemia-reperfusion: role of TLR4/NF-kappaB signaling pathway. Int J Clin Exp Med 2015; 8: 1737–1746.
74. Hamacher-Brady A, Brady NR, Gottlieb RA. The interplay between pro-death and pro-survival signaling pathways in myocardial ischemia/reperfusion injury: apoptosis meets autophagy. Cardiovasc Drugs Ther 2006; 20: 445–462.
75. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006; 114: I270–I274.
76. Chen Y, Rothnie C, Spring D, Verrier E, Venardos K, Kaye D et al. Regulation and actions of activin A and follistatin in myocardial ischaemia-reperfusion injury. Cytokine 2014; 69: 255–262.
77. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005; 68: 224–234.
78. Hua F, Ha T, Ma J, Li Y, Kelley J, Gao X et al. Protection against myocardial ischemia/ reperfusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism. J Immunol 2007; 178: 7317–7324.
79. Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL et al. Modulating Toll-like receptor mediated signaling by (1–43)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res 2004; 61: 538–547.
80. Ehrentraut H, Weber C, Ehrentraut S, Schwederski M, Boehm O, Knuefermann P et al. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur J Heart Fail 2011; 13: 602–610.
81. Louwe MC, Karper JC, de Vries MR, Nossent AY, Bastiaansen AJ, van der Hoorn JW et al. RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice. Int J Cardiol 2014; 176: 788–793.
82. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552–559.
83. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38: 72–83.
84. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309: 1154–1162.
85. Fang H, Chen J, Lin S, Wang P, Wang Y, Xiong X et al. CD36-mediated hematoma absorption following intracerebral hemorrhage: negative regulation by TLR4 signaling. J Immunol 2014; 192: 5984–5992.
86. Jacobsen JH, Watkins LR, Hutchinson MR. Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction. Int Rev Neurobiol 2014; 118: 129–163.
87. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin Ther Pat 2011; 21: 927–944.
88. Wagner KB, Felix SB, Riad A. Innate immune receptors in heart failure: Side effect or potential therapeutic target? World J Cardiol 2014; 6: 791–801.